Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Pfizer, BioNTech confirm FDA panel supports EUA for COVID vaccine in children » 18:20
10/26/21
10/26
18:20
10/26/21
18:20
PFE

Pfizer

$43.56 /

+0.39 (+0.90%)

, BNTX

BioNTech

$292.41 /

-2.63 (-0.89%)

Pfizer (PFE) and BioNTech…

Pfizer (PFE) and BioNTech (BNTX) announced that the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee voted 17 to 0, with 1 abstention, to recommend the FDA grant Emergency Use Authorization for the companies' COVID-19 vaccine in children 5 to less than12 years of age. VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy. The committee reviewed the totality of scientific evidence shared by the companies, including results from a Phase 2/3 randomized, controlled trial that included ~4,500 children 5 to less than12 years of age. Participants in this age group received a two-dose regimen of 10-microgram doses administered 21 days apart, one-third of the 30-microgram dose used for people 12 years and older. This dose level was carefully selected for use in the trial based on safety, tolerability and immunogenicity data evaluated as part of a dose-ranging study. The Phase 2/3 trial showed a favorable safety profile, robust immune responses and a vaccine efficacy rate of 90.7% in participants without prior SARS-CoV-2 infection, measured from 7 days after the second dose. The Data Monitoring Committee for the study has reviewed the data and has not identified any serious safety concerns related to the vaccine. "We appreciated the opportunity to present our clinical data demonstrating the safety and high efficacy of our COVID-19 vaccine in children 5 to under 12 years of age," said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. "COVID-19 is an ongoing threat for the more than 28 million young children in this age group in the U.S., as they remain at risk for this infection. About 10% of all weekly U.S. cases occur in children 5 to under 12 years of age with a potential risk of complications. In addition, immunizing children will help to get us closer to herd immunity, with the potential to stem the pandemic sooner. We thank the FDA advisory committee for their review and positive recommendation in support of Emergency Use Authorization to help protect this young population."

ShowHide Related Items >><<
PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

Hot Stocks
Trillium shareholders approve acquisition by Pfizer subsidiary » 17:16
10/26/21
10/26
17:16
10/26/21
17:16
TRIL

Trillium Therapeutics

$17.97 /

+0.055 (+0.31%)

, PFE

Pfizer

$43.56 /

+0.39 (+0.90%)

Trillium Therapeutics…

Trillium Therapeutics (TRIL) announced that its securityholders approved a statutory arrangement with PF Argentum, a wholly-owned, indirect subsidiary of Pfizer (PFE) at the special meeting of Trillium securityholders. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates. The arrangement is subject to court and regulatory approvals and clearances, as well as other customary closing conditions. Subject to the satisfaction of such conditions, the transaction is expected to be completed in Q4 of 2021 or the first half of 2022.

ShowHide Related Items >><<
TRIL Trillium Therapeutics
$17.97 /

+0.055 (+0.31%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

TRIL Trillium Therapeutics
$17.97 /

+0.055 (+0.31%)

08/24/21 Craig-Hallum
Trillium Therapeutics downgraded to Hold at Craig-Hallum
08/24/21 Craig-Hallum
Trillium Therapeutics downgraded to Hold from Buy at Craig-Hallum
08/24/21 JMP Securities
Trillium downgraded to Market Perform from Outperform at JMP Securities
08/23/21
Fly Intel: Top five analyst downgrades
PFE Pfizer
$43.56 /

+0.39 (+0.90%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
TRIL Trillium Therapeutics
$17.97 /

+0.055 (+0.31%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

TRIL Trillium Therapeutics
$17.97 /

+0.055 (+0.31%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

TRIL Trillium Therapeutics
$17.97 /

+0.055 (+0.31%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

Hot Stocks
FDA panel votes in support of Pfizer-BioNTech vaccine for kids aged 5-11 » 16:19
10/26/21
10/26
16:19
10/26/21
16:19
PFE

Pfizer

$43.56 /

+0.39 (+0.90%)

, BNTX

BioNTech

$292.41 /

-2.63 (-0.89%)

An FDA Advisory Committee…

An FDA Advisory Committee voted 17 yes to 0 no with 1 abstention that the totality of scientific evidence available supports the benefits of the Pfizer (PFE) and BioNTech (BNTX) COVID vaccine when administered as a 2-dose series outweigh its risks for use in children 5-11 years of age.

ShowHide Related Items >><<
PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

BNTX BioNTech
$292.41 /

-2.63 (-0.89%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

PFE Pfizer
$43.56 /

+0.39 (+0.90%)

Conference/Events
FDA Vaccines and Related Biological Products Advisory Committee to hold meeting » 08:25
10/26/21
10/26
08:25
10/26/21
08:25
PFE

Pfizer

$43.16 /

+ (+0.00%)

, BNTX

BioNTech

$295.01 /

+16.63 (+5.97%)

The Committee discusses a…

The Committee discusses a request to amend Pfizer-BioNTech's Emergency Use Authorization (EUA) for administration of their COVID-19 mRNA vaccine to children 5 through 11 years of age in a virtual meeting to be held on October 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
PFE Pfizer
$43.16 /

+ (+0.00%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

PFE Pfizer
$43.16 /

+ (+0.00%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
PFE Pfizer
$43.16 /

+ (+0.00%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

PFE Pfizer
$43.16 /

+ (+0.00%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

PFE Pfizer
$43.16 /

+ (+0.00%)

PFE Pfizer
$43.16 /

+ (+0.00%)

Hot Stocks
BioNTech to initiate construction of mRNA vaccine facility in Africa in mid-2022 » 08:12
10/26/21
10/26
08:12
10/26/21
08:12
BNTX

BioNTech

$295.01 /

+16.63 (+5.97%)

BioNTech announced that…

BioNTech announced that the Company plans to initiate the construction of the first state-of-the-art manufacturing site for mRNA-based vaccines in the African Union in mid-2022. This is the next step in BioNTech's efforts to implement sustainable end-to-end vaccine supply solutions on the African continent. The decision is the result of a meeting between Rwanda's Minister of Health, Dr Daniel M. Ngamije, Senegal's Minister of Foreign Affairs Aissata Tall Sall, Ugur Sahin, M.D.,CEO and Co-Founder of BioNTech and Sierk Poetting, COO of BioNTech as well as Dr Sabin Nsanzimana, Director-General of Rwanda Biomedical Centre and Dr Amadou Alpha Sall, Directeur-General of Institut Pasteur de Dakar in Kigali, Rwanda. The meeting occurred upon the invitation of the kENUP Foundation and took place as a side-event of the Second Ministerial Meeting of the African Union and the European Union and resulted in a Memorandum of Understanding. This comes after the parties signed a Joint Communique at a previous meeting in Berlin on August 27, 2021. The parties agree to jointly establish end-to-end manufacturing capacities for mRNA-based vaccines in Africa starting immediately. BioNTech has finalized the construction plans and ordered the assets, which will be delivered by mid-2022. The new manufacturing facility could become the first node in a decentralized and robust African end-to-end manufacturing network enabling an annual manufacturing capacity of several hundreds of million mRNA vaccine doses. BioNTech plans to develop and implement a scalable construction network based on the expertise and learnings from the ramp-up of the Company's production facility in Marburg. To enable an expedient set-up of production capacities according to GMP standards, BioNTech will start with the construction and validation of a first production line enabling the manufacturing of drug product for about 50 million of e.g. COVID-19 vaccine doses per year, once fully operational. The capacity will be increased sequentially by adding further manufacturing lines and sites to the manufacturing network on the continent, supporting the production of several hundreds of millions of mRNA vaccine doses. BioNTech will initially staff, own and operate the facility to support the safe and rapid initiation of the production of mRNA-based vaccine doses. BioNTech plans to transfer manufacturing capacities and the know-how to local partners. Therefore, BioNTech, the Rwanda Development Board and Institut Pasteur de Dakar in Senegal agreed to swiftly build-up the required human resources capacity and systems so that the partners can take over ownership and operational duties. In parallel, the Republic of Rwanda and the Institut Pasteur de Dakar have committed themselves to scale-up fill and finish capacities to complete the local end-to-end manufacturing process. In addition, BioNTech is in discussions about an expansion of the current partnership with Cape Town-based vaccine manufacturer Biovac, which is part of the Pfizer-BioNTech COVID-19 vaccine manufaturing network.

ShowHide Related Items >><<
BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

Conference/Events
FDA Vaccines and Related Biological Products Advisory Committee to hold meeting » 04:55
10/26/21
10/26
04:55
10/26/21
04:55
PFE

Pfizer

$43.16 /

+ (+0.00%)

, BNTX

BioNTech

$295.01 /

+16.63 (+5.97%)

The Committee discusses a…

The Committee discusses a request to amend Pfizer-BioNTech's Emergency Use Authorization (EUA) for administration of their COVID-19 mRNA vaccine to children 5 through 11 years of age in a virtual meeting to be held on October 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
PFE Pfizer
$43.16 /

+ (+0.00%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

PFE Pfizer
$43.16 /

+ (+0.00%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
PFE Pfizer
$43.16 /

+ (+0.00%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

PFE Pfizer
$43.16 /

+ (+0.00%)

BNTX BioNTech
$295.01 /

+16.63 (+5.97%)

PFE Pfizer
$43.16 /

+ (+0.00%)

PFE Pfizer
$43.16 /

+ (+0.00%)

Monday
Conference/Events
FDA Vaccines and Related Biological Products Advisory Committee to hold meeting » 15:15
10/25/21
10/25
15:15
10/25/21
15:15
PFE

Pfizer

$43.02 /

-0.145 (-0.34%)

, BNTX

BioNTech

$291.49 /

+13.11 (+4.71%)

The Committee discusses a…

The Committee discusses a request to amend Pfizer-BioNTech's Emergency Use Authorization (EUA) for administration of their COVID-19 mRNA vaccine to children 5 through 11 years of age in a virtual meeting to be held on October 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
PFE Pfizer
$43.02 /

-0.145 (-0.34%)

BNTX BioNTech
$291.49 /

+13.11 (+4.71%)

PFE Pfizer
$43.02 /

-0.145 (-0.34%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
BNTX BioNTech
$291.49 /

+13.11 (+4.71%)

10/22/21
Fly Intel: Top five analyst initiations
10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
PFE Pfizer
$43.02 /

-0.145 (-0.34%)

BNTX BioNTech
$291.49 /

+13.11 (+4.71%)

PFE Pfizer
$43.02 /

-0.145 (-0.34%)

BNTX BioNTech
$291.49 /

+13.11 (+4.71%)

PFE Pfizer
$43.02 /

-0.145 (-0.34%)

PFE Pfizer
$43.02 /

-0.145 (-0.34%)

Friday
Initiation
Fly Intel: Top five analyst initiations » 10:00
10/22/21
10/22
10:00
10/22/21
10:00
BNTX

BioNTech

$282.87 /

-3.79 (-1.32%)

, CVAC

CureVac

$38.61 /

-1.525 (-3.80%)

, MRNA

Moderna

$326.96 /

-12.51 (-3.69%)

, PRGS

Progress Software

$51.00 /

+0.34 (+0.67%)

, API

Agora

$28.53 /

+0.38 (+1.35%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BioNTech (BNTX) initiated with a Hold at Deutsche Bank. 2. CureVac (CVAC) initiated with a Hold at Deutsche Bank. 3. Moderna (MRNA) initiated with a Sell at Deutsche Bank. 4. Progress Software (PRGS) initiated with an Overweight at JPMorgan. 5. Agora (API) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
PRGS Progress Software
$51.00 /

+0.34 (+0.67%)

MRNA Moderna
$326.96 /

-12.51 (-3.69%)

CVAC CureVac
$38.61 /

-1.525 (-3.80%)

BNTX BioNTech
$282.87 /

-3.79 (-1.32%)

API Agora
$28.53 /

+0.38 (+1.35%)

BNTX BioNTech
$282.87 /

-3.79 (-1.32%)

10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
CVAC CureVac
$38.61 /

-1.525 (-3.80%)

10/22/21 Deutsche Bank
CureVac initiated with a Hold at Deutsche Bank
07/01/21 Berenberg
CureVac COVID vaccine data may be enough for EU approval, says Berenberg
06/30/21
CureVac announces COVID vaccine candidate demonstrates 48% efficacy
06/30/21 B. Riley
B. Riley downgraded Vaxart to Neutral on 'riskier development path'
MRNA Moderna
$326.96 /

-12.51 (-3.69%)

10/22/21 Deutsche Bank
Moderna initiated with a Sell at Deutsche Bank
10/15/21
Fly Intel: Top five analyst upgrades
10/15/21 Piper Sandler
Moderna upgraded to Overweight from Neutral at Piper Sandler
PRGS Progress Software
$51.00 /

+0.34 (+0.67%)

10/22/21 JPMorgan
Progress Software initiated with an Overweight at JPMorgan
09/24/21 Oppenheimer
Progress Software price target raised to $60 from $54 at Oppenheimer
09/24/21 Citi
Progress Software price target raised to $50 from $48 at Citi
08/06/21
Fly Intel: Top five analyst initiations
API Agora
$28.53 /

+0.38 (+1.35%)

10/22/21 JPMorgan
Agora initiated with an Overweight at JPMorgan
05/10/21 Macquarie
Agora price target lowered to $60 from $80 at Macquarie
03/23/21 Macquarie
Agora initiated with an Outperform at Macquarie
01/05/21 China Renaissance
Agora initiated with a Buy at China Renaissance
PRGS Progress Software
$51.00 /

+0.34 (+0.67%)

MRNA Moderna
$326.96 /

-12.51 (-3.69%)

CVAC CureVac
$38.61 /

-1.525 (-3.80%)

BNTX BioNTech
$282.87 /

-3.79 (-1.32%)

API Agora
$28.53 /

+0.38 (+1.35%)

  • 28
    Jan
MRNA Moderna
$326.96 /

-12.51 (-3.69%)

CVAC CureVac
$38.61 /

-1.525 (-3.80%)

BNTX BioNTech
$282.87 /

-3.79 (-1.32%)

PRGS Progress Software
$51.00 /

+0.34 (+0.67%)

MRNA Moderna
$326.96 /

-12.51 (-3.69%)

CVAC CureVac
$38.61 /

-1.525 (-3.80%)

BNTX BioNTech
$282.87 /

-3.79 (-1.32%)

API Agora
$28.53 /

+0.38 (+1.35%)

MRNA Moderna
$326.96 /

-12.51 (-3.69%)

CVAC CureVac
$38.61 /

-1.525 (-3.80%)

API Agora
$28.53 /

+0.38 (+1.35%)

Hot Stocks
Walgreens says now offering Moderna, J&J vaccine booster shots nationwide » 09:32
10/22/21
10/22
09:32
10/22/21
09:32
WBA

Walgreens Boots Alliance

$49.16 /

+0.77 (+1.59%)

, MRNA

Moderna

$339.49 /

+6.68 (+2.01%)

, JNJ

Johnson & Johnson

$163.32 /

-0.44 (-0.27%)

, PFE

Pfizer

$42.86 /

+0.07 (+0.16%)

Walgreens (WBA) announced…

Walgreens (WBA) announced that eligible individuals can now receive Moderna (MRNA) and Johnson & Johnson (JNJ) COVID-19 vaccine booster shots in stores nationwide following the Food and Drug Administration Emergency Use Authorization and new guidance from the Centers for Disease Control and Prevention. This follows FDA authorization of a Pfizer (PFE) booster dose on Sept. 24. As part of this new guidance, eligible populations may also choose to receive a dose different from the one they received for their initial series, Walgreens noted.

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$49.16 /

+0.77 (+1.59%)

PFE Pfizer
$42.86 /

+0.07 (+0.16%)

MRNA Moderna
$339.49 /

+6.68 (+2.01%)

JNJ Johnson & Johnson
$163.32 /

-0.44 (-0.27%)

WBA Walgreens Boots Alliance
$49.16 /

+0.77 (+1.59%)

10/15/21 Truist
Walgreens Boots Alliance price target raised to $56 from $52 at Truist
07/06/21 Barclays
Walgreens Boots Alliance price target lowered to $53 from $55 at Barclays
07/02/21 Truist
Walgreens Boots Alliance price target lowered to $52 from $58 at Truist
07/02/21 Deutsche Bank
Walgreens Boots Alliance price target lowered to $52 from $55 at Deutsche Bank
MRNA Moderna
$339.49 /

+6.68 (+2.01%)

10/22/21 Deutsche Bank
Moderna initiated with a Sell at Deutsche Bank
10/15/21
Fly Intel: Top five analyst upgrades
10/15/21 Piper Sandler
Moderna upgraded to Overweight from Neutral at Piper Sandler
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
JNJ Johnson & Johnson
$163.32 /

-0.44 (-0.27%)

10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
10/20/21 Baird
Intuitive Surgical price target raised to $370 from $350 at Baird
10/08/21 BTIG
Legend Biotech price target raised to $65 from $55 at BTIG
10/04/21 Piper Sandler
Xencor price target raised to $75 from $63 at Piper Sandler
PFE Pfizer
$42.86 /

+0.07 (+0.16%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
WBA Walgreens Boots Alliance
$49.16 /

+0.77 (+1.59%)

PFE Pfizer
$42.86 /

+0.07 (+0.16%)

MRNA Moderna
$339.49 /

+6.68 (+2.01%)

JNJ Johnson & Johnson
$163.32 /

-0.44 (-0.27%)

WBA Walgreens Boots Alliance
$49.16 /

+0.77 (+1.59%)

PFE Pfizer
$42.86 /

+0.07 (+0.16%)

MRNA Moderna
$339.49 /

+6.68 (+2.01%)

JNJ Johnson & Johnson
$163.32 /

-0.44 (-0.27%)

WBA Walgreens Boots Alliance
$49.16 /

+0.77 (+1.59%)

PFE Pfizer
$42.86 /

+0.07 (+0.16%)

MRNA Moderna
$339.49 /

+6.68 (+2.01%)

JNJ Johnson & Johnson
$163.32 /

-0.44 (-0.27%)

WBA Walgreens Boots Alliance
$49.16 /

+0.77 (+1.59%)

PFE Pfizer
$42.86 /

+0.07 (+0.16%)

MRNA Moderna
$339.49 /

+6.68 (+2.01%)

JNJ Johnson & Johnson
$163.32 /

-0.44 (-0.27%)

Hot Stocks
Pfizer, BioNTech Covid vaccine 90.7% effective in children, FDA says » 08:05
10/22/21
10/22
08:05
10/22/21
08:05
PFE

Pfizer

$42.86 /

+0.07 (+0.16%)

, BNTX

BioNTech

$286.47 /

+16.78 (+6.22%)

In briefing documents…

In briefing documents ahead of the advisory panel meeting on October 26, the FDA said Pfizer (PFE) and BioNTech's (BNTX) vaccine efficacy against laboratory-confirmed symptomatic Covid-19 occurring at least seven days after dose two in evaluable participants aged 5 to 11 without evidence of prior SARS-CoV-2 infection was 90.7%. There were no cases of severe Covid-19 and no cases of MIS-C reported as of the data cutoff date. It is notable that the earliest reported and confirmed Covid-19 case in this analysis was in July, with most occurring in August and September, therefore all confirmed cases have been reported during a time that the highly transmissible delta has been the predominant SARS-CoV-2 strain in circulation in the U.S. and globally the FDA added. "These data show that the two-dose primary series of BNT162b2 10 microgram given to children 5 to less than12 years of age confers a high degree of protective efficacy against COVID-19 during a period when the Delta variant of concern predominates in the US," it said. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$42.86 /

+0.07 (+0.16%)

BNTX BioNTech
$286.47 /

+16.78 (+6.22%)

PFE Pfizer
$42.86 /

+0.07 (+0.16%)

10/15/21 H.C. Wainwright
H.C. Wainwright ups Codexis target, says Pfizer pact may be growth driver
10/14/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis after today's curve ball'
10/14/21 Stifel
Codexis' large order being from Pfizer, not Merck, a 'plot twist,' says Stifel
10/12/21 Morgan Stanley
Pfizer price target raised to $48 from $45 at Morgan Stanley
BNTX BioNTech
$286.47 /

+16.78 (+6.22%)

10/22/21 Deutsche Bank
BioNTech initiated with a Hold at Deutsche Bank
10/06/21 Jefferies
BioNTech initiated with a Hold at Jefferies
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
PFE Pfizer
$42.86 /

+0.07 (+0.16%)

BNTX BioNTech
$286.47 /

+16.78 (+6.22%)

PFE Pfizer
$42.86 /

+0.07 (+0.16%)

BNTX BioNTech
$286.47 /

+16.78 (+6.22%)

PFE Pfizer
$42.86 /

+0.07 (+0.16%)

PFE Pfizer
$42.86 /

+0.07 (+0.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.